THROMBOSIS UK
(A Company Limited by Guarantee)
REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2025
Regtstered Charity No: 1090540
Company No: 4354472
L3174-2fj

THROMBOSIS UK
Registered Charity No: 1090540
Company No: 4354472
TRUSTEES, ANNUAL REPORT FOR THE YEAR ENDFD 31 JANUARY 2025
REFERENCEAND ADMINISTRATION DETAILS:
TRUSTEE AND MANAGEMENT
Andrea Louise Croft
Dr Matthew Robert Fay
Professor lan Maxwell Franklin (Resigned as Chair on 22.10.2024)
Simon Hart
Professor Beverley Jane Hunt OBE (Appointed as Co-chair on 22.10.2024)
Stephane Jaglin
Professor Sirnon Noble (Retired 04.09.2025)
Robin Offord
Janet Morgan (Appointed as Co-chair on 22.10.2024)
Nusaiba Masnurah
CEO
Jo Jerrome (Resigned effective from 31.08.2025)
Tiffany Richards. Inierim CEO (Appointed on 05.08.2025)
Secretary
Professor Beverley Jane Hunt OBE
REGISTERED OFFICE
Couch Bright King & Co
2 Tolherst Court
Turkey Mill Business Park
Ashford Road
Maidstone
Kent ME14 5SF
AUDTfoRS
Couch Bright King & Co
Chartered Accountants
2 Tolherst Court
Turkey Mill Business Park
Ashford Road,
Maidstone
Kent ME14 5SF
SOLicfTORS
Stone King
28 Ely Place
London ECIN 6TD
BANKERS
National Westininster Bank PLC
Malda Vale
Elgin Avenue
127 Kilburn Road
London NW6 6JL

THROMBOSIS UK
Registered Charity No: 1091)540
Company No: 4354472
TRUSTEES, ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2025
The Trustees present their annual report and the financial statements for the year ended 31 January 2025.
The f￿anCIal statements have been prepared in accordance with the accounting policies set out on pages 18 to 19,
and comply with the Charities Act 2011, thL Stalement of Recommended Practice (SORP) applicable to ch￿ltieS
prcparing their accounts in accordance with ihe Financial Reporting Standard applicable ID the UK Republic
of treland (FRS 102), published in October 2019 and the CoTnpanics Act 2006.
Thrombosis UK is a charitable company limiicd by guarantee. incorporated on 16 January 2002 and registered as a
charity on 12 February 2002. It has no share capital. Accordingly. the report and fmancial statemenls also comply
with the requirements of the Companies Aci 2006.
Opening statement from Thrombosis UK co-chairs
For many years. we have been exceptionally fortunate to have stability at Thrombosis UK in tern]s of a dedicated
team and boJrd of trustees.
This year that changed. Our chair, lan Franklin. who successfully led the charity for nine years. including the
challenges of the pandemic. chose to step down. and our long-serviT]g patient support and helpline lead AnT]ya, left
to pursue other interests.
Both individuals have made a lasting contribution to the organisation. lan's calm and considered leadership has
beeD iTnmense. Over her 17 years. Annya has supported countless patients and family members better understand
and adapt to life after VTB.
Throughout this time, the other employees and supporters of the charity continued to exceed expectations and
ensure Thrombosis UK provides a breadth of support to our community. Thanks to that team, it bas been a
successful and busy y￿.
The Charity has delivered a wide range of valuable and qll￿lty educational and patient support activities. We have
continued our efforts to Taise awareness of thrombosis and expanded our digital channels as a way to reach more
people. We have also taken steps to enhance our governance and securiry and continue to support and undertake
research.
With the changes within the charity and externally, it was with some trepidation that the iwo of us took on the
responsibility of co-chairs. We are commiiied io coniinuing the work lan began before the pandemic- reviewing
our long-tern] strategy outlining how we best can save lives and prevent suffering caused by blood clots.
As we ]￿k to the year ahead, there is rnuch to be proud of - and much still to do. Strengthening the ch￿Ity's
long-lerni sustainability will be a key focus. including exploring new ways to diversify and grow our income so that
we can expand our reach and irnpact evcn funber.
We would like io close with thank5. A heartfelt thanks to our fellow trustees and uur employees. who have led the
charity with resilience And purpose.
And to our supporters and volunteers - those individuals who tAke on anwing challenges and give so generously of
Iheir time. Without you. Thrombosis UK would not be her¢. Thank you to each Rnd every one of you.
J Morgan & B Hunt
Co-chairs. Throtnbosis UK

THROMBOSIS UK
Registered Charlty No: 1090540
Company No: 4354472
TRUSTEES, ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2025
OBJECTIVES AND STRATEGIES
Thrombosis UK was established to advance medical science in relalion to tILe dÈagnosis, cause5, Prevention, alleviation.
managemenL and cure of thrombosis and for the Promotion of l(nowledge and public education of the understanding and
aW￿elless of thrombosis. Using the powers confetred by the Memorandum of Association, Thrombosis UK ain]s to
fund:
A range of studies looking ai why and how a thrombosis occurs.
R￿earch into the management and the improvement of current treaLTnents available.
An education prOgrarnn￿ that infonns people about the causes, effects, prevention, and recommended
management of thrombosis.
Provide a network of support for those affected by thrombosis.
ORGANISATION AND STRUCTURE
The Board of Trustees, who are also Directors OF the company, govern Thrombosis UK.
The Trustees have the power to appoint, and remove any member. any member to act as Secretary to the Charity and all
vote on the appointment of the Chair. Treasurer. and other Honorary Officers.
The charity seeks to ensure Trnstees are appointed to fulfil the changing and on-going needs of the charity's activilies
and outcomes. A Trustee job description is agreed when vacancies become available to ensure existing and new
Twstees have Cl￿AtY on their roles and they each bring skills that complement and benefit Thrombosis UK.
New Trusiees are appointed with the unanimous approval of existing Trusiees, All Trustees give freely of their time and
expertise and receive no remuneration for their worL
The day-to-day administration of the Charity is the responsibility of the Chief Executive Officer employed on a 0.8
pernlanenl FTE contraci. The current CEO resigned with effect from 31 August 2025, and an Interim CEO has been
appointed with effect from 5 August 2025.
The Patient Support and Helpline Lead Tole is employed on a 0.8 pennanent contract. This role has been vacanf since 12
D￿eT￿ber 2024 pending review. The Tole of Admin and Fundraising Administrator on a 0.6 permanent contract, was
increased to 0.8 fn)m I Septe￿ber 2024, for the Ye￿ under review. The role became vacant effective from 4 July 2025.
In 2022 the Charity appointed a Clinical Psychologist on a 0.5 two-year FfE contract starting l February 2022.
Following review, tbis was extended in January 2024 for a further two years until 31 January 2026.
In Septernber 2024. the Trnstees appointrd a temporary 0.4 Consultant as Operations Lead until 31 May 2025.
AIMS AND ACTIVITIES
The Charity aims to promote greater awareness and understanding of venous thromboembolism (VIE) to improve:
Prevention of avoidable blo(Kl clots.
Timely detection and prompt diagnosis of VTE.
Appropriate management that improves patient outcomes.
Timely support and education to enable patients to restore their well-being and health.
To support achievement of this, the Charity concentrates on three key areas.
Awareness
Education
Research

THROMBOSIS UK
Registered Charity No.. 1090540
Company No: 4354472
TRUSTEKS, ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2025
AWARENESS
Raising awareness remains a key obje¢five of the charily's work. encompassing both specific awareness activities
and creating oppothnities through linked initiatives.
During 2024. the charity exlended its reach and awareness through rnultiple activities. including=
- Exhibiting in Wales at several Aderidd's 'Lel's Get Physical, campaign in Carniarthen and Wrexham.
- Having a table exhibition at the Royal Welsh Show.
Presenting in-person and within online Tneetings lo trainee tlledical studcnis, nursing networks and industrylwork
settings.
Online. the charity reviewed its social media platfonns. expanding to include Blue Sky and streamlining its LinkedIn
presence via a business page. Next step5 will be to expand training. focusing on design and AI, to promote
engagement.
Working in collaboratio7) with like-minded European patient groups to develop an awareness-raising social media
campaign - 'Think Thrombosis, is due to launch in early 2025 and will consolidate key messages around awareness,
knowledge and recognition of the common risks. signs and symptoms for blood clots.
In July 2024. the new Thrombosis UK website was launched. Developed following liaison and focus group meetings
with stakeholders who regulaTly use the website, the new plaiforni is much more user-friendly, easier to navigate.
and provides illcreased opportunities for the charity, including an e-commerce shop. an accredited educational
platform area, and can be I￿gelY managed by staff. FeedbaLk in the r￿st few months has been extren]ely EKlSitive
from patient and HCP users.
Popular patient infonnation resources have been Tefrcshed with new designs but all in keeping with the Thrombosis
UK brand and fresh new website, while those needing to be updatcd were completed during 2024 as well a8 new
titles added - including CeiebraL Venous Sinus Thrombosis (CVST), vfE in children and adolescents and.
Thrombosis Prevention in Lower Limb Immobilisation. In the first quarier after launch, the sit¢ had welcomed just
over 10,IKJO visits.
Monitoring site data, the team are pleased to see 'Organic Sear¢h' &s one of the top ways the website is found.
reflecting search engine results are 'finding' us! Direct. organic S￿la1 and refeLTal are the next most common.

THROMBOSIS UK
Registered Charity No: 1090540
Company No: 4354472
TRUSTEKS, ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2025
Education
The charity is comnLiiied to advancing education and understanding of venous thromboembolism (VTE) among
patients, healthcare providers, and the publi¢.
In 2024, we continued to host the highly regarded 'National Thrombosis Week. (NTW'24) and 'Let's Tallc Clots.
(LTC'24) virtual conferences, while <ilongside these. we established regular online patient meetings and focused
events.
Both virtual conferences received continuing Professional development credits (CPD) from the Royal College of
Pathologists.
Nfw'24 featured 21 sessions, welcomed 54 faculty rnernbe￿. secured 17 CPD credils. and attracted 2,733
rcgistrations from healthLare professionals. While primarily UK-based, our atteT]dee% rcpresented 54 different
countries! The conterence incorporated webinars. small group 'round table. discussions. and an array ol wster
exhibitions and oral PTesentalions. Feedback listed agcnda topics. ease of access to live aT]d catch-up recordings aT]d
CPD accredilation as the top three reason8 delegates chose to registcr.
LTC'24 set a new reLord with 2.985 registrations from healthcare and allied pri)fessionaIs across 59 countries.
demonslrating our global impact. Live Webin￿ attendance ranged from 131 to 520, and follow-up recordings
consistently drew over 940 view5. Notably, we experienced increased interaction during the live week. with
participants actively engaging in quesiions and discussions.
Despite facing unexpected challenges within the organisation from mid-2024, we successfully hosted 11 Patient
Informatlon sessions and regular 'Coffee and Chat, meettngs. We were fortunate to have the support of leading
specialists in VTE. including Prof Paul Bennett, Andrea Croft. Dr. Susie Shapiro. and Dr. Will Lester, alongside
patient representatives, including ex-patient Trustee and patient advocate, Shaun Kinghorn.
Our Let's Talk Clots app has proven to be an invaluable educational resouT¢e. achieving 5,900 downloads and
maintaining a remarkable 92% activity rate after download. The number of hospiLqls and medical settings promoting
the app has surged, with rising requests for app posters and cards from primary care providers.
In August 2024, NHS Scotland endorsed eight Thrombosis UK patient resources, including app promotion postcards,
with the NHS Healthier Scotlalld logo. This endorsemeni allows all Scottish medical settings to utibse these resources
seamlessly, without needing local reviews. This achievernent has been enthusiastically welcomed by both the
Thrombosis UK t&qm and Scottish VTE healthcare professiollals.

THROMBOSIS UK
Registered Charity No: 1090540
Company No: 4354472
TRUSTEE&i' ANNUAL REPORT FOR THE YEAR FNDED 31 JANUARY 2025
RESEARCH
Phase One of the 'Dete£t VTE, project, aimed at overcoming barriers to the diagnosis of VTE, kicked off at the start of
2024. A total of 49 GP practices from across mainland UK volunteered to porticipate. collectively providing care for
over 400,(K)O people. The initial audit w&s completed by June 2024, leading to an in-depth analysis of the data. We are
gratethl to have secured pro bono support from Costello Medical to assist us in tbis important work.
Detect VTE audit was the first of its kind, looking at the journey of individuals diagnosed with a VTE in the previous
12 months and their journey in the eight weeks prior to confirn)ed diagnusis. IAX)king at presentatioll symploms, risk
faLlors. l￿d the number of presentations in the eight weeks before diagnosis was madc. as well as where individuals
presented duriDg this journey. A paper detailing this work is due to be published in mid-2025.
Thc woik could not have been accomplished without voluntary involvemeT]t frotn the primary practices and
Thrombosis UK'S Trustee and GP Lead. Dr Matthew Fay. This involvement should be both acknowledged and
sinccrcly thanked. Following the audit. each practice received a detailed report of their praclic¢'s audit. was given the
opportunity to have a l-l discussion session with th¢ Medical Lead (Dr Matthew Fay) and an in-house educalional
session for all practice members. Approximately three-quarters requested the l- I feedback discussion. and around one-
third. an educational event.
The work with Detect ITE now moves to Phase Two. and the development of an rr clinical tool to provnpt
investigation should suspicion of vfE be indicated.
Early work on a ¢Stocklngs Otr campaign, working in collaboration with the British Society for Haematology (BSH)
has been initiated, with a freedom of inforn)ation request (FOI) to NHS Procurement seeking to secure dala on the
number of compression stocking purchased by NHS England over a 12-month period (O1108123-31107￿4).
Although not possible to have exact figures due to procurement pathways and variation in Coding, we &sked NHS
Supply Chain (80 IYo+ QTdered via them), who confmed more than 2.726,723. burther work on the Stockings Off
campaign is expected io siart mid-2025.
The charity's involvement in research s￿dIeS has increased with regulaT Tequests to secure 'Patient and Public
Involvenient, (PPI). Patient supporters have been very interested in being involved. and the chaTity h&8 hosted a range
of online meeting5. including:
What Is PPI?_ intended for a patient audicnce.
What PPI involvement should and shO￿ld not include- intended for a healthcare professional audience.
Individual collaboration with UK-TReN, HacmSTAR and Oxford University Hospilals on focused topics
seeking PPI involvement and discussion on research design and priority areas for vfE-related research.
As interest and support have grown, Thrombosis UK'S Professional Advisory Committee (PAC) worked to develop a
'Research Policy, for the charity, so that reS￿nSe to requests can always be balanced and reflect the values and focus
of the ¢harity.

THROMBOSIS UK
Registered Charity No: 1090540
Company No: 4354472
TRUSTEES, ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2025
REGAIN
Thrombosis UK'S RFGAIN project initially intended to provide free. online access to clinical psychological support
for individuals didgnosed with Vaccine-induced Immune Thrombocytopenia and Thrombosis (VITT). but who were
unable 10 access local psychological support. Since 2023. the L"mphasis of tbe REGAIN service has been to provide a
general support service to people who have experienced a non-VITT-related thrombosis. The service has had three
key foci:
Providing one-t(Fonc or group support. directly working with people who have expeTienccd some for￿ of vrE.
2. Further developing ihe infornmtion PTovisiun accessible on the new wcbsifr for people eX￿rienCillg
psychological dislress followin¥ VTE and extending the focus lo wider behavioural change.
Development of a tr￿nIng package for health professionals related to communication skillq. inilially available
via the new website in a non-interaLtive forn￿t, and then as 'live' iDteTactivc workshops.
IndividuallgTOUP SUPPOrt
Group support has been provided by a Sequence of four weekly workshops over a peri(NJ of a month. and repeated every
three months. The first sequence has now been completed. and the next planned. Topics coping with worry. panic.
poor sleep and 'getting back to norn]al.'
Access to individual support has developed with increased prominence on the new website, although fewer I general are
requiring additional support with the intr(Mluction of group sessions However, some health care providers who were
aware of the REGAIN service ate utilizing the referra] option patients (including some late-idenlified VITT patients) into
one-to-one sessions and a wider gmup of ¢liTJicians.
Patient edueation
New and more detailed support booklets have been developed to support the existing psychological onllne infonnation.
These provide extended inforniation on managing worry, panic and sleep. In addition, a 'how to stop, smoking
infommtion b￿klet has been developed as this appears to be a key concern for many vfE patients.
Health care professlonal education
A planned series of lectures, patient stories and health pmfessional experiences focusing on a range of topics around the
topic of communication now being finalised in time for the new website. Six toplcs (including why bother to
communicate, the basics of communication. and negotiating patient decision making) are being developed into an
education package for health care professionals and expected to launch in 2025 with the intention fhat these will seek to
secure CPD accreditation.
INTERNAL
The past year has been one of challenges. change and OppOr￿nitieS for Thronthosis UK. TiTne has been invested in
securing the stwcture. including rr security and governance. Addition of new policie8 that safeguard. guide and
fonnalise procedures. including the 'Abusive, Persistent or vexatious Complaints Policy.
We have been extremely fortunate to secure pro bono support from nvo leading companies - Costello Medical. one of
the mosl established independent agencies delivering medical cornmunications and health economic services, and
Curious Health. an exceptional team of healthcare digital communications specialists. Work with both continues and 15
making a significant impact on the ouicome of projects that each has agreed to supporL
It was also a year in which we said farewell to a long-serving member of staff, Annya Stephen5 Boal, who will be
much missed by colleagues and the many patients and families who benefited from her knowledge, under51anding and
care during her 17 years of service to Thrombosis UK.

THROMBOSIS UK
Registered Charity No: 1090540
Company No: 4354472
TRUSTEES, ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2025
FUNDIi4ISING
Supporters took part in many events across the UK, kmd along with new we also welcomed repeat fundraisers and
donors who so kindly continue to support Tlwombosis UK.
Over the past year, fundraising efforts have secured over 80 unique events, which collectively raised a total of
£89,227, averaging £l.115,34 per ￿ndraISe[. This impressive achievement is a testament to the dedication and
generosity of our suptK)rteTS.
Among the many incredible fundraisers. Lewis Owen led the way by raising an impressive £14.000. He was followed
by Lauren James, who raised over £6,IK)O. while Lyndsey Nichols contributed niore than £3,5(K). Andrew Woods and
Jane Enticott each raised just over £3,(X)O. Their remarkable efforts have tnade a meaningful impact on the work of
Thrombosis UK.
Review has indicaied that marathons and runs are not only popular but have led to the raising of substantial funds,
while wa]ks. challenges, Imd general events have also made significant contribulions. Although les8 'popular' evenls
such as skydives. clin)bs. and swims do impact awareness raising.
Continuing to diversify event opportunities nmintains broad appeal. however, planning is key with so many events in
spring and summer.
Thrombosis UK is immensely gratefi]I to all who fundraise and donate to the charity for our work lo Continue.
Tragically, suptK)rt often comes after personal suffering or loss, and Thrombosis UK would like supporters and
reiterate that iheir fundraising helps to make a significant difference to understanding, raising awareness of and
supporting many individuals affected by venous thromboembolism. Due to their efforts. we can continue and be there
for anyone at risk of, diagnosed with or who has lost a loved one due to vfE. to talk. share information and help
them through the impact of thiombosis.
FINANCIAL REVIEW
During the year ended 31 January 2025 the charily made a deficit of £79.213 (2024: surplus of £255,442). Total
incorning resources saw a decrease of 42Yo and expenditure increased by almost 48% in the y&gr. The material deCr&￿e
in incoming resources was as a result of Thrombosis UK successfully receiving restricted grant monies in year ended
31 January 2024 (see Note 3 on page 19).
The virtual events and aclivilies incurred a generally lower expenditure requirement. A significant proportion of the
increase in expenditure during the year was attributable io the charity's strategic decision to appoint a temporary
consultanf to fulfil the role of operations lead, alongside a higher number of travel fellowship grants awarded compared
to the previous year. The economic and political uncertainty continues 10 affect the ability OF the charity to
meaningfully forecast corporare and individual funding commitments and. as with last year, although the charity
budgeted to meet its planned ch￿Itable activities through funds raised in the year it was prepared to have to utilise a
proportion of its general unrestricted reserves if necessary.
The net assets of the charity have been retained and have decreased from £667,220 in 2024 to £588,007 and this fits
with the reserves policy of the charity. General unrestricted funds show a small deficit of £2,225 for the year.
The Statement of Financial Activities is presented on page 15.

THROMBOSIS UK
Registered Charity No: 1090540
Company No: 4354472
TRUSTEES, ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2025
PLANS FOR FUTURE PERIODS
The extended adopiion of virtual events, in particul￿ educational webinars. conferences, and meetings. has continued
to enable the charity's work to grow and extend across:
Reach.
Global collaborations.
Ease of access for patients. the general public and healthcare professionals to access inforniation,
support, and training.
The online platfonn has not only proven to be more cost-effective, but also received extremely positive feedback
from faculty, attendees, and sponsors. While the recording of sessions ensured a lasting legacy to access high quality
education.
The inaugural meeting for the newly fornied Thrombosis UK 'Professional Advisory Commiiiee, ￿Ac), was held
in 2024. Fornied with representatives from across the UK fron] health care and patient supporters, this coinmittee
will..
To represent VTE stakeholders across the UK.
Identify and inforni Thrombosis UK on relevant and key areas of VTE which should be included in the charity's
strafrgy for delivering its 'Awareness, Research and Care, goals.
Provide input and guidance on update or development of resources, conference agendas and advocacy activities
across the UK NHS systenis.
Be a first line referee for grant proposals or applications.
Represent Thrombosis UK as an ambassador.
In reviewing plans for 2024125, while Thrombosis UK is mind￿1 of the benefits of personal interaction the charity
is keen io enable increased a¢¢ess and the virtual platforni and recording of webinars is currently enabling both
greater access and a learning legacy. However. we are rnindful that continued monitoring is important and so the
charity, along with review from the PAC, will Continue to carefully consider feedback, access and opportunity to
ensure we are delivering in the most effective and efficient style suitable and welcomed by UK healthcare
practitioners.
REFERENCE AND ADMINISTRATION DETAILS
A Board of ten Trnslees, who are also Directors of the company, govern Thrombosis UK. The Trnstees have the
power to appoint and remove any member to act as Secretary 10 the charity and ajl - vote on the appoiniment of the
Chairman, Treasurer, and other Honorary Officers. The charity seeks to ensure trustees are appointed io fulfil the
changing and on- going needs of the charity's activities and outcomes. New trusfres are appointed with ihe
unanimous approval of existing trustees.
All Trnstees give freely of their time and expertise and receive no remuneration for their work as trus￿eS. TILe
current list of t￿stee$, who acted throughout the period of review. is given on page one.
Trustees unaDiTnously a8reed to adopt a rotational model for the role of Medical Director of Thrombosis UK, with
each appointee in post for two to three y&grs. In April 2016 Professor Simon Noble accepted an invitation to this role
laking up the post in June 2016 until his retirement in 2025, with tbe objective of allowing for fresh ideas to
percolate through the organisation. In November 2020 the Trustees agreed to extend retaining current directors for
an extended 12 months while Governance work continued with the objective io write Trustee roles and job
descriptions and develop a new Constitution. This work continues, and agreement was again in 2023 for this to be
extended in order to implemeni a robust succession plan for Trustees so that skills, knowledge and experience are
not lost, but instead, built on to secure the safe governance of Thrornbosis UK.
Trustees. meetings are held a minimum of twice per year. Email correspondence is used to keep Trustees updated in
between meetings and the CEO meets with Thrombosis UK'S Medi￿1 Ltads and lor Chair of Trustees between four-
six times per Ye￿ to discuss projects and agreed strategic and directional development.

THROMBOSIS UK
Registered Charlty No: 1090540
Company No.: 4354472
TRUSTEES, ANNUAL REPORT FOR THE YEAR ENDED 31 JANUAR Y 2025
TRUSTEES, RESPONSIBILITIES IN RELATION TO THE FINANCIAL STATEMENTS
The trustees (who are also directors of Thrombosis UK for the purposes of company law) dre responsible for preparing
the Tni%tces' Report and the financial statemeJ]ts in dLLordance with applicable law and United Kingdom Accounting
Standards (United KingdoTn Generally Accepted Accounting Ptaclice).
Company law requires the lrnstees to picpare financial statements for each fJnaT]Cidl year, which give a true and fair
view of the state of affairs of the chaTiLthle company and of the incoming resources and application of resollrce￿.
includAng the incorne and eX￿nditure, of the charitahle company for ihe year.
ID preparing these financial statements. the trnstees are required to:
Select suitable accounting policies and then apply them consistently.
Observe the Meth(￿5 and principles in ihe Charities Statement of Recomrnended Practice (SORP).
Make judgements and estimates that are reasonable aT]d prudenL
Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the
charitable company will continue in operation.
The trustees are responsible for keeping proper accounting records that disclose wilh reasonable accuTa¢y at any time
the financial position of the charitable company and enable them to ensure that the financial statements Comply with the
Companies Act 2006. They are also responsible for safeguarding the assets of the charitable compally and hence for
taking reasonable steps for the prevention and detection of fraud and other iffegularities.
In accordance wilh company law, the Trustees certify that..
80 far as we &￿e aware, there is no relevant audit inforniation of which the company s auditors are unaware. and
as Trnstees we have taken all the steps that we ought to have taJ(en in order to make ourselves aware of any
relevant audit Inforn￿tion and to establish that the company's auditors are aware of that Inforn￿ll0n.
The trnstees are responsible for the maintenance and integrity of the COT￿rate and fmancial infonnation included on
the charitable company's website. Legislation in Éhe United Kingdom governing the preparation and d5ssemination of
fmancial statements may dilfer from legislation in other jurisdictions.
At]DTfoRS
The Auditors, Me%%rg Couch Bright KiT]g & Co., have expressed their willingness to conlinue in offjce and a
resolution pmposing their re-appoiT]Iment will be put to the Trnstees at the forthcoming Annual GeT]eTal Meeling.
SMALL COMPANY EXEMPTION
This report has been prepared in accordance with the provisions applicable to companies entitled to the small Companies.
exemption.
STATEMENT AS TO DISCLOSURE OF tNFORMATION TO AUDITORS
The Trustees who were in office on the date of approval of the financial statements have confirnied, as far as they are
aware. that there is no relevanl audit infonnation of which the auditors are unaware. Each of the Trnsiees have confinned
that they have taken all the steps that they ought to have taken as Trustees in order to make themselves aware of any
relevxnl audit information and to establish that it has been communicated to the auditors.
io

THROMBOSIS UK
Registered Charity No: 1090540
Company No.: 4354472
TRUSTEES, ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2025
RESERVES POLICY
In the course of the development of the charity we vjill take account of the need to have reserves, and a policy. to honour
future funding committnents that we We will also ensure that funds are sufficient to cover one year's charitable
aclivity plus sufficient fvnds to cover ail operating costs of the charity.
RISK ASSESSMENT
We consider the systems we have in place for the day-to-day operation of Thrombosis UK io be appropriate to our
current size of operation, but we are aware that as we grow, we will need io develop and implement procedures and
reporting regimes lo mitigate the risks associated with running a charitable company.
PUBLIC BENEFIT
The Trusiees ¢onfirni. to the best of their knowledge and belief, that they have complied with Section 4 of The Charities
Act 2011 in respect of having due regard ro Public Benefit Guidance published by the Charity Commission,
Approved by the Tn]stees on:
September 2025
Janet Morgan
Co.Chair

INDEPENDENT AUDITORS, REPORT TO THE MEMBERS OF
THROMBOSIS UK
Registered Charity No: 1090540
Opfinfion
We have audiied the financial statements of Thrombosis UK for the year ended 31st January 2025 which comprise the
primary statements such as the Statement of Financial Activities including Income and Expenditure Account, thc Balance
Sheet, the Statement of Cash flows and the related notes. The financial reporting framework that has been applied in their
prcparation is applicable law and United Kingdom Generally Accepted Accounting Practice including FRS 102 'The
Financial Reporting SLindard xpplicable in the UK and Republic of Jreland (United Kingdom Generally Accepted
Accounting PrdcÉiLL").
In our opinion the finanLial staiements:
give a true and fair view of the state of the chdrilable conipany's affairs as at 31 st January 2025 and of its incoming
resources and application of resources. including its income and expcndilure, for the year then ended;
have been properly prepaTed in accordance with United Kingdom Gcnerally Accepted Accounting Practice applicable to
smaller entities-
have been prepared in accordance with the requirement5 Qf the Companies Aci 2(Ki6.
Basis for opinion
We conducted our audit in accordance with International Standards QD Auditing (UK) (ISAS (UK)) and applicable law. Our
responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial
statements section of our retKTrrt. We are independent of the charitable company in accordance with the ethical requirements
that are relevant to our audit of the fmancial statemenis in the UK, including the FRC'S Ethical Standard, and we have
lfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have
obtained is sufficieni and appropriate to provide a basis for our opinion.
Conclusions relating to going concern
In auditing the financial statements, we have concluded that the trustees, use of the going concern basis of accounting in the
preparation of the financial statements is appropriate.
Based on the work we have perfonned, we have not identified any material uncertainties relaiing to events or conditions thaL
indlvidually or collectively, may cast significant doubt on the charitdble company's ability to continue ds a going concern for
a tLYiod of at least twelve months from when the financial Statell￿ntS are authorised foT ISSue.
Our responsibilitics and the responsibilities of thc trusiees with respect to going concern are described in the relevant sections
of this report.
Other Inforn￿￿On
The other infonnation comprises the infoTmation included in the trustees annual reporL other than the fmancial statements
and our auditor's report theicon. The trustees are ￿sponSible for the other information contained within the an￿￿1 report.
Our opinion on Ihe financial statements does not cover the other infornlation and, except to the extcnt othenvise explicidy
staled in our report, we do not express any forni of a88ur2nce conclusion ihereon.
Our Tesponsibilily is to read the other infoThation and, in doing so. consider whether the otheT inforniation is materially
inconsisteni with the fmancial staterDcniS or our knowledge obtained in the course of the audil or otherwise appears to be
n￿teriallY misstated. If we identify such material inconsistencies or apparent maierial misstatements. we a￿ required to
detertnine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we
have perfornied. we conclude that there is a Material misslarement of this other information, we are required to report that
fa¢t.
We have nod]ing to report in this regard.
12

INDEPENDENf AUDITORS, REPORT TO THE MEMBERS OF
THROMBOSIS UK
Registered Charity No: 1090540
Opfinlons on other mattsrs prescribed by the Companies Act 2006
In our opinion. based on the work undenaken in the course of the audit:
the inforn￿lI0ll given in the trnstees, report (incorporating the directors, report) for the financial year for which the
financial statements are prepared is consistent with the financial statements. and
the truslees. report has been prepared in accordance with applicable legal requirements.
Matters on which we are requlred to report by exception
In the light of our knowledge dT]d understanding of the chariLqble company and its environment obtsined in the course of the
audit. we have T]Ot idcntified material mis5tatcmenls in the trustees. report.
We have nothing to report in respect of the following Tnatters in relation to which thc Companies Act 21)06 requires us to
report to you il, in our opinion:
adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches
not visited by us. or
the financial statements are nor in agreernent with the accounting records and returns: or
certain disclosures of trustees, remuneralion swified by law are not nmde. or
we have not received all the infonnation and explanations we requi￿ for our audit. or
the trustees were not entitled to prepare the fmancial stateTnentg in accordance with the small companies, regime and take
advantage of the small companies. exemptions in preparing ihe directors, report and frotn the requirement to prepare a
strategic report.
Responsibilitles of trustees
As explained more fully in the Trustees, Responsibilities Statement set out on Pdge 10, the Trnstees (who are also the
directors of ihe charitable Compdny for the purposes of the company law) rcsponsible for the prcparation of the fjnancial
statements and for being satisfied that they give a lrne and f￿r view, and for such internal control as the trnstees detern)ine 18
necessary to enable the preparation of financial statements that aTe free from material misstatemenL whether due to fraud or
tn preparing the fmancial statemeT]tS. the trustees re8pon%iblc for assessing the charitable company'4 dbi]iiy to continue as
a going concern. disclosing, as applicable, Tnatter8 related to going concern and using the guing concern basis of accounting
unless the truslees either intend to liquidate the charitable company or to cease operations, or have rcalistic alternative but
to do so.
Auditor's responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole aTe free from malerial
isslatement, whether due to fraud or e￿Or. and to issue an auditor's reporr thai includes our opinion. Reasonable assurance
is a high level of assurance bul is nol a guarantee that an audit conducted in accordance with ISAS (UK) will always detect a
materia] misstatement when it exists. Misstatemenis can ￿lse from fraud or em)r and are considered material if. individually
or in the aggregate, they could reasonably be expected to influence the economic decisions of users tsken on the basis of
these financial statements.
13

INDEPENDENT AIJDITORS, REPORT TO THE MEMBERS OF
THROMBOSIS UK
Registered Charity No: 1090540
Auditor's responsibilities for the audlt of the financial stalements {......Continued)
Jrregularities. including fraud. are instances of non-compliance with laws and regulations. We design Procedures in line with our
responsibilities. outlined above. to detect material misstatements in Tespect of Irregul￿1t1e8, including fraud. The specific
procedures for this engagem￿llt and the extent to which thesc are capable of detecting irregularities, inLluding fraud is detailed
below:
We bave.
Obtained an understanding OF the legal and regulatory fra￿CwOrk applicable to the entity and how the cntily is complying
with that ftatnewurk.
Obtained an ullderslanding of the entity's policies and pmcedures on compliance with laws and regulations. including
docunlentation of any instances of non-cumpliance.
Identified the laws and regulations that have significance in the conlcxt ol the entity.,
Obtained an understanding of the enlily's risk assessment process, including the risk of fraud.
Assess¢d and evaluated the susceptibility of the entity's financial statements to llLat¢rial misstatement, through C￿Or and
Implemented procedures to enable the identification and testing of unusual or unexpected journal entries.
Evaluated the assumptions and judgements used by management within significmt accounting estimates and assessed if
these Indica￿ evidence of management bias.
Tested significant trallsactions, in particular the evaluation of the business rationale for any which appear unusual or outside
th¢ company's nornial course of business.
Reviewed the fmancial statements and tested the disclosures against supporting documentation,.
Communicated relevant matters (including those above) io all members of the audit team to ensutt they underst(x)d the risks
SP￿lfie to the entiry and the audit procedures planned to mitigaie these.
Because of the inherent lin]itations of an audit, there is a risk that we will not delect all irregularities, including those leading to a
material misststLrnent in the fmancial sratsments or non-compliance with regul&tion. This risk increases the more thai compliance
with a law or regulaiion is removed from the events and transactions ￿flected in the financial ststements, as we will be less likely lo
become aware ot instsnces of non-compliance. Thc risk is ￿s0 greater ￿gardIng irregularilies occurring due to fraud rather than
eIroT, as Iraud involves intentional Lonceaiment, forgery. collusion, omission or miSTcpresentation.
A further description of our responsibilities for the dudit ol Ihe financi￿ statetncnts is located on the Financial Reporting
Council's website at: www.frc.org.uklaudiiorsresponsibilities. This dcscriplion fonns part of our auditOT'S reFKIrt.
Use of our report
This report is made solely to the Ch￿Itable company's rnembers, as a body, in accordance with Chapter 3 of Part 16 of the
Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's mernbers those
lllatters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent pern)itted by
law. we do not accept or assume responsibility to aT]yone other than the charitable company and its members as a body. foT
our audit work, lor this report, or for the opinions we have fonned.
Ms Tarwa Mo
For and on behalf of
Couch Bright King & Co
Chartered Accountants &
Statutory AuditOTS
A FCA (Senior Statutory Auditor)
2 Tolherst Court
Turkey Mill Business Park
Ashford Road. Maidstone
Kent ME14 5SF
99 September 2025
14

THROMBOSIS UK
Registered Charity No: 10905401
Company No: 4354472
STATEMENT OF FINANCIAL ACTIVITIES
(Including Jncome and Expenditure Account)
FOR THE YEAR ENDED 31 JANUARY 2025
Year
to
31.01.2025
Tolal
Funds
Year
Unrestricted
General
Designated Restricted
Funds
Funds
Funds
31.01.2024
Total
Funds
Notes
Income:
Donations. legacies and gifts
249.019
249,019
478.468
Incomefrom Charifable activities,.
FAlucational meetings
EveT]ts - Sponsorship
970
20,356
970
20,356
23,750
Incomefrom orher trading activities,.
Online shop
Awareness Literature
Other Income
630
703
337
337
Investment Income
Bank Interesi
22.544
22.544
3,367
Total income
293,226
293,226
506.918
Expenditure
Costs of raising ￿ndS
4,908
4.908
4,702
Costs of charitable activities
290,543
740
76.248
367,531
246.774
Total Expendlture
295,451
740
76,248
372.439
251.476
Net income and Net movements
in funds
(2,225)
{740) (76,248)
(79.213)
255,442
Transfers
Net movements in funds
(2,225)
(740) {76,248)
(79,213)
255,442
Reconciliation or rund$
Total funds
At l FebrLWy 2024
382.307
740
284,173
667.220
411,778
Total Funds
At 31 January 2025
14
380,082
207.925
588,(K)7
667.220
The statement of financial activili¢s includes all gains and losses recognised in the year.
All income and expenditure derive from continuing activities.
15

THROMBOSIS UK
Registered Charlty No: 1090540
Con)pany No: 4354472
BALANCE SHEET
AS AT 31 JANUARY 2025
Notes
2025
2024
Fixed Assets
Tangible fixed assets
io
Current A&sets
Debtors
12
17.312
22,027
Cash ai bank and in hand
586.045
667,574
603.357
689,6A)I
Credilors (amounts falllng
due within one yeAr)
13
15,350
22,381
Net Current Assets
588,007
667,220
Net Assets
588,007
667,220
Represented by:
Restrlcted funds
14
207,925
284.173
Designated Funds
14
740
Unrestricted funds
General funds
14
380.082
382.307
Total unr£stricted funds
588,007
667,220
Total funds
588,(K)7
667,220
The accounts have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006
relaling to small companies.
Approved by the Trustees on
September 2025
Signed on
ir behalf by
Slmon Ha
Trustee
Janet Morgan
Co-chair
16

THROMBOSIS UK
Registsred Charity No: 1090540
Company No: 4354472
STA TEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 JANUARY 2025
Note
2025
2024
Cash flows from operating aetivitles:
Net movements in fvnds for the year
(79,213)
255,442
(79,213)
255,442
Movements in working capital
Di￿dendS and interest from investments
(22,544)
(3.367)
Decrease/(Increase) in Debtors
4,715
5,912
(Decrease)Itncrease in Creditors
(7,031)
3,269
Net cash generated by operating activities
(104,073)
261.256
Cash flows from investing aetivities:
Dividends and inleresi from invesunents
22,544
3.367
Cash used in investing activilies
22,544
3.367
Increase in cash and cash equivalents
(81.529)
264,623
Cash and cash equivalents at beginning of the year
667,574
402,951
Cash and cash equivalents at the end of the year
586.045
667,574
17

THROMBOSIS UK
Registered Charlty No: 1090540
Company No: 4354472
NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 31 JANUARY 2025
i)
Statutory Infurniation
a) Company Stat￿$
The charity is a company limited by guarantee, incorporated in England and Wales. The registered offjce is
2 Tolherst Court. Turkey Mill Business Park, Ashford Road, Maidstone. Kent ME14 5SF. The principal
office address is PO Box 1242, Chew Magna. Brislol, BS40 8WG.
The members of the collipany are the trustees named on page l. In the event of the charity beiT]g wound
p. the liability ill iespect of the gudrantee is limited to £1 per member of the charity.
b)
Charilable Status
Thrombosis UK is a regAsteTed charity. registration number 1090540 dnd in consequence is exempt from
tsxation on income aTisin¥ from and expended on its charitable activities.
2)
Accounting Policies
The PTincipal accounting policies, all of which have been applicd consistently throughout the year. are set
oul below:
Basis of Preparation
The financial slatements have been prepared in accordance with Accounting and Reporting by Charities..
Statement of Recommended Practice applicable to Charities prepaTing their accounts in accordance with the
Financial Reporting Sfv￿dard applicable in the UK and Republic of trelaT]d issued in October 2019. the
Financial Reporting Stand￿d applicable in the United Kingdom and Republic of Ireland (FRS 102), the
Charities Act 201 l. the Companies Act 2006 and UK Generally Accepted Accounting Practice.
Thrombosis UK meets the definition of a publi¢ benefit enlity under FRS 102. Assets and liabilities are
initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting
policy notes.
b)
Functional and presentation currency
The company's functional and presentation currency is GBP.
Going Concern
The Trustees continue to adopt the going coDcern basis in preparing the financial statements and confirm
there are no material uncertaintses about the charity's ability to continue as a going concern.
d)
Flxed Assets and Depreclation
Depreciation is charged on a straight-]ine basis. in order to write off the assets over their useful economic
lives as follows-
Computer and Other Equipment over 3 y&trs
Assets acquired Under a Value of £1,5(￿) are cbarged to the Statement of Financial Activities in the year of
acquisition.
Income and Expenditure recognition
Income is recognised when the charity has entitleTnelll to the funds, any performancc condiLions attached io
the items of income have been Tnet, it is probable that the iT]coTne will be received. and the amount can be
m&2sured reliably. Incorne is deferred to match the period of the ternis of the grant docuMenti￿lon or ternis
of agree￿ent where applicable.
The Charity. ID Common with many others of a similar size and organisation. derives a substantial
pro￿nIOn of its income from voluntary donations. Such donations are recognised and eniered into the
accounting records when they are rcceived. Oiher income. such as bank interest. is accounled for on an
accruals basis.
On receipt, donated services are recognised on the basis of the value of the gift to the Charity which is the
amouJ]t the Charity would have been willing to pay to obtain services or facilities of equivalent economic
benefit on the open market. a corresponding amouni is then recognised in expenditure in the period of
receipt.
All expenditure is accounted for on accrnals basis.
18

THROMBOSIS UK
Reglstered Charity No: 1090540
Company No: 4354472
NOTES TO THE ACCOUNTS
FOR TItE YEAR ENDED 31 JANUARY 2025
Debtors and creditors receivable I payable within one year
Debtors and creditors with no siaLed interest rate rcceivable or payable within one year recorded at
traDsactiOT] price. Any losses arising from impairmeni are recognised in expenditure.
g)
Unrestricted Fund
Unrestrictrd funds are donations, gifts and other incoming resources receivable or generated for the objects
of the Ch￿ltY without further specified purpose and are available as geneIal ￿ndS or for purposes as
designated and agreed by all the Trustee5.
h)
Deslgnated Fund
Designated funds (where applicable) a￿ unrestricted funds earmarked by the Trustees for particular
PUTposes.
i)
Restricted Fund
Restricted fi]nds are donations, gifts and other incoming resources receivable or are generated for the
objects of the charity with a specified PUry>se. They can only be used in accordance with the donor's wish
or by the ternis of a public appeal.
21)25
202A
3)
Donalions and gifts
Restricled
Research
REGAIN Programme
Education Grant
Detect VTE Audit Study
ISTH Grant 2022
1.000
753
16.0
255.020
28.673
UnrestTiCted
Donations
Gift Aid
Donated Services
158.785
14,046
76.188
157.721
19.301
249,019
478.468
The number of general donations we have received during the year has seen a small increase compared to prior year.
Thrombosis UK is irntnensely grateful io all of those who have organised a fundraising event for the charity.
* Donated services coTt)prise pro bono support received from Costello Medical, who provided researcb data attalysis
for the Detect VTE audit, and from Curious Health. who contributed comTnuni¢ation and PR services in support of
our awareness campaign.
2025
2024
4)
Income from charitable actfivitlos
Educational Meetings
Events - Sponsorship
970
20,356
23,750
21,326
23,750
5)
Income from other tradlng activities
Online shop- ebay sales
Awareness Literature
703
630
337
337
1,333
19

THROMBOSIS UK
Registered Charity No: 1090540
Company No: 4354472
NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 31 JANUARY 2025
6)
Costs of raising funds
Donations
Events
1,993
2,915
2,956
1.746
4,908
4.702
Analysls of eosts of charitable actlvltles
R(*ricted Designated I
Unrestricted
2025
2024
Research Grant
Travel Fellowship Grants
Awareness Resources
Awareness Lilerature
Thrombosis Education
Dondted Scivices (Note 3)
Website & App Costs
Support Costs (Note 8)
Governance Costs (Note 8)
54,207
54,207
12,IIK)
39,612
12,929
345
76,188
11.059
152,426
8.665
6,097
12.1(Ki
28,857
12,929
345
76.188
11.059
141.140
8.665
10,755
26.806
40.492
9,454
16,395
135,806
11,724
11,286
Total
76,248
291,283
367,531
246.774
8)
Analysis of Support and Goven)ance costs
Thrombosis UK initially idcn(ifies ils SilPPOrt costs which relate to the governance function and then the remalning
support costs are apportioned as follows.
General Governance
Support
Function
Total
2025
Basis of
apportlonment
Trustee and other business rneeting8
274
274
Invoiced events
Sa1￿]eS, wages and related cost5
121.888
121.888
Allocated on time
General Office
13,401
13,401
Invoiced events
Audit fees
6.930
6,930
Governance
Consultancy Fees
13,104
13.104
Governance
Legal and other professiona] fees
4.033
1,461
5.494
Governance
152.426
8,665
161,091
20

THROMBOSIS UK
egistered Charity No: 1090540
Company No: 43S4472
NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 31 JAIYUARY 2025
Analysis of Support 8nd Governance costs (......Contlnued)
General Governance
Support
Function
Total
202A
Basis of
apportionment
Tn]slee and other business meetings
309
309
Invoiced events
Salaries. wages and related costs
124,538
124,538
Allocated on time
General Office
11.268
11.268
Invoiced eveDIs
Audit fees
6,600
6,6(Y)
Governance
Consultancy Fees
Governance
l£gal and other professional fees
4,815
4.815
Governance
135,806
11.724
147.530
2025
2024
9)
Staff Costs
Salaries
Employers National Insurance
Pensions
110.682
5,374
5.832
113,260
5,395
5.883
121,888
124.538
The average number employed during the year was
There are no employees with emoluments above £60,IKK).
The Key Management Personnel of the ch￿IlY comprise the T￿SteeS aDd the Chief Executive Officer. The Trustees
have not received any remuneration for their work as Trustees. The total employee benefits of the Key Management
Personnel were £49,720 (2024.. £48,931).
io)
Fixed Assets
Com
ui
Total
Cost
At isr Febrnary 2024
Addilions
4.697
4,697
4.697
4.697
De redation
At I" February 2024
Cha￿e for year
4.697
4,697
4,697
4,697
Net Book Value 31 ¥ January 2025
Net Book Value 3151 January 2024
21

THROMBOSIS UK
Regtstered Charity No: 1090540
Company No: 4354472
NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 31 JANUARY 2025
2025
2024
ii)
Cash and cash equivalents
Cash at Bank
586,045
667,574
12)
Debtors
Gift Aid
Prepayment5 & A¢¢rued Income
470
16,842
5,439
16.588
l7,312
22.027
13) Creditors: Amounts falling due Mqthin one year
Other taxes
Grants Payable
Other creditor & Accruals
Deferred Grants
2,360
2,900
10,089
3,172
7,900
11.309
15,350
22,381
14)
Movement in Funds
Atl"
February
2024
Incoming
Outgoing
Resources Resources
Transfers
At 31st
January
2025
Restricted funds:
Research
REGAIN Programrne
VTE Grand Appeal
ISTH
Detect VTE Audit Study
6.459
12,960
3,143
14.069
247,542
6.459
12,960
3,143
3.314
195,009
10.755
52,533
Tot81 restricted funds
284.173
76,248
207,925
Unrostricted funds:
Designated Funds
REGAIN Programme
740
740
General Funds
382.307
293,226
295.45 I
380.082
Total unrestrlcted funds
383.047
293,226
296,191
380.082
se of Restricted Fullds
Research- There was no donation received ￿WardS the Thrombosis UK Research Fund in the year (2024: £1,000).
REGAINProgramme-The REGAIN Programme, launched by the charity in 2021, aims to address the
psychological impact of Venous Thromboembolism (VTE). including complicaiions associated with COVID-19.
The initial development of the programme was ￿nded by a restricied grant received in 2021, specifically allocated
lo supp3rt research and patient support activities relating to VTE and Vaccine-Induced Itnmune Thrombotic
Thrombocytopenia (VITT). During the year. no further restricted income was received in relation to the PTogramme
(2024: £753). Total expenditure during the year amounted to £12,960, resulting in a closing restricted fund balance
of £nil (2024: £12,960).
22

THROMBOSIS UK
RegAstered Charity No: 1090540
Company No: 4354472
NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 31 JANUARY 2025
of Restricted FuDds
.ContiDued
ISTH - In 2023124, Thrombosis UK received a restriLted grant of approximately £28.5(K) (equivalent to $37.500)
from the International Society on ThroTnbosi8 and Haemostasis USTH) to support the developmeT]t of a Venous
Thrombi)eTnbolism (vfE) Patient Inlonnation App, designed to impmvc patient access to essential inforniation
about vfE. No additional income was received during thc year, and eXpendi￿re totalled £10,755. The restricted
nd caTried forward a closing balance of £3.314 at the year end.
se of Unrestricted Funds
General funds balance includes:
(i) Designated Funds- REGAIN Programme
Following the lallnch of the REGAIN clinical psychology research service programme in 2021, Ihe Trnstees
established a designated fund in the year ended 31 January 2022 to support the ongoing development and
delivery of this programme. No additional income was received for the programme during the year {2024.. £nil).
This fund has been tully utilised in the year.
(li) General - ThroTnbo¥is UK is conlmitted to raising awareness and advancing throvnbosis research in the UK. The
Trnstees hdvc decided that as much as possible of the money donated by the general public will be used towards
these objectives.
Events - Sponsorship fees receivcd to enable the chariry to widen the Pllblic and Health Professionals. awareness
of thron]bosis and thc relaled issues. Sponsorship fe&s of £20,356 were received in the year to support the
National Thrombosis Week in May 2024 and the 'L£t's Ta]k Clots. Virtual Conference held as part of World
Thrombosis Day celebrations in October 2024.
Transfers between fvnds
There were no transfers between funds in the year.
15)
Capital Commitments
There are no ourstanding comtnitments as at 31 January 2025.
16)
Contingent Liabilities
There are no contingent liabilities to report as at 31 January 2025.
17)
Post Balance Sheet Events
There are no adjusting OT non-adjusting events to report as at 31 January 2025.
18)
Tr￿tee Remuneration
The Trustees have not received any remuneration for their work as Trustees. Expenses totalling £274 (2024: £309)
have been reimbursed to two Trustees.
19)
Related Party Transactions
There were no Related Party Transactions in the year.
23

THROMBOSIS UK
Registered Charity No: 1090540
Comppdny No: 43S4472
NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 31 JANUARY 2025
20)
Taxation Slaths
The company being a registered charity {No.10905401 is not liable to Income and Corporation Taxes on its
charitable activities.
21)
Analysis of net assets between funds
Unrestricted
Funds
D&signated
Funds
Restricted
Funds
Total
2025
Fixed assets
Cash and current Tnvestments
Other current assetsl(Liabilities)
378,120
1.962
207,925
586,045
1,962
Total
380.082
207,925
588,(X)7
Unrestrleted
Funds
Deslgnated
Funds
Restricted
Funds
Total
2024
Fixed assets
Cash and current Investments
Oiher current assetsl(Liabilities)
382,661
(354)
740
284,173
667.574
(354)
Total
382.307
740
284,173
667,220
24